However, sales across critical divisions were lackluster, with key products such as the respiratory syncytial virus (RSV) vaccine, Arexvy, missing expectations by 21%, and Shingrix sales falling ...

The business was hit by lower demand for its RSV vaccine Arexvy and its best-selling shingles vaccine Shingrix. Analysts expected vaccine sales of 2.71 billion pounds, according to consensus ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and delayed ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for respiratory syncytial virus (RSV ...